bluuebunny/crossref_metadata_2025_split huggingface dataset:
P03-114 - Service User Experience of the Use of Acupuncture for the Treatment of Schizophrenic Symptoms
Authors: Ronan P. , Brinton M. 
Published: June 2010

ObjectivesThe purpose of this paper is to highlight the position of mental health patients in terms of treatment choice, advanced directives and evidence to support complementary and alternative medicines (CAM).MethodsHere, a patient with a long-standing diagnosis of schizophrenia outlines her experience of treatment with antipsychotic medication and contrasts this with the success she has had with the use of acupuncture for her symptoms. The evidence behind CAM for mental health problems, including schizophrenia is explored, as is the reliance on antipsychotic medication for people who are acutely mentally ill, over and above any prior requests individuals may make for CAM to be included in their treatment programme.ResultsFollowing several unsatisfactory treatment episodes with antipsychotic and antidepressant medication, Madlin introduced acupuncture as an adjunct treatment. This enabled her to live independently in the community for over 8 years. Although she continues to be susceptible to psychosis, her experience of acupuncture is that it makes a significant improvement to her quality of life. Madlin feels that access to acupuncture for inpatients might further improve recovery rates and relationships with mental health workers.ConclusionsMental Health patients are increasingly asking for access to CAM and the evidence is improving. This might be a good time to for psychiatrists to consider CAM treatment possibilities where patients request them or where there is evidence to support their use.
P03-119 - Pharmacogenetic Studies of Olanzapine, Perazine and Ziprasidone in Paranoid Schizophrenia
Authors: Samochowiec J. , Tybura P. , Frydecka D. , Beszłej A. 
Published: June 2010

Literature data revealed that efficacy and side effects of antipsychotic treatment are influenced by multiple genes interactions. Polymorphic variation is likely to contribute substantially in this matter. Pharmacogenetic studies will help to determine which drug and dosage are best for each individual patient.The aim of our study was to find:1.Genetic markers influencing susceptibility of paranoid schizophrenia. The polymorphisms of DRD2 (-141C del/ins, Taq1A, egzon8), DAT, 5HT2a, 5HTT_LPR, COMT, MAO A and GRIK3 genes were studied.2.Relationships between different gene variants and the treatment efficacy measured by the PANSS.The group of 201 patients with paranoid schizophrenia consisted of 95 men (mean age 34) and 105 women (mean age 35). There were no significant differences between the groups according to the studied gender. Males patients had a significantly earlier age of onset but the duration of illness was similar in both gender groups. The patients were treated randomly with perazine, olanzapine or ziprasidone. The control group consist of 230 healthy volunteers ethnically, gender and age matched.Results1.No differences were found in the allelic distribution in the investigated genes polymorphisms between the whole schizophrenics and the control group.2.Associations between DAT: A9 allele, DRD2: del 141C allele, DRD2: Taq1A A1 allele, COMT: Met/Met genotype, MAOA: 4VNTR allel (males only) and GRIK3: SER allel with non responding patients were found.
P03-130 - Development and Use of QuIRC in Germany
Authors: Schuster M. , Schuetzwohl M. , Kallert T. 
Published: June 2010

ObjectiveTo develop a toolkit (QuIRC) for assessing the living conditions, care and human rights of people with long term mental illness in psychiatric and social care facilities.MethodsThe QuIRC was developed by research partners across ten countries: UK; Germany; Spain; Czech Republic; Bulgaria; Italy; Netherlands; Poland; Greece and Portugal. Its content was informed by triangulation of the evidence on critical components of care collated from: a review of care standards in each country; an international literature review; and Delphi exercises. Its final format was agreed by an international panel of rehabilitation and recovery experts. QuIRC scores were compared against service users’ quality of life, autonomy, experiences of care and markers of recovery to assess whether the QuIRc could provide a proxy-assessment of the unit’s promotion of service users’ autonomy and Recovery.ResultsThe finalised tool was used to interview managers from 21 units throughout Germany. One hundred and eighty-eight service users were also interviewed. QuIRC domain ratings were compared by facility type and with service user assessments. The QuIRC’s ability to deliver assessments relevant to Germany’s established systems of change at local, regional and national level will be discussed.
P03-132 - Redefining Outcome Measures in Schizophrenia: Integrating Social & Clinical Parameters
Authors: Shrivastava A. , Shah N. , Bureau Y. 
Published: June 2010

Schizophrenia is a complex neurobehavioral disorder for which there are many promising new treatments. There is, however, a discrepancy in outcome measure reports when obtained from patients, relatives, caregivers, or professionals making it difficult to determine the level of recovery in patients. The reason for the lack of agreement may be due to the limitations of the measurement tools themselves, which are not comprehensive and may measure different aspects of outcome. Alternatively, it could be that the conceptual understanding of outcome and in turn recovery requires development. Unfortunately for one of the above reasons or both, patients assessed as “recovered” remain excluded from mainstream society. We are of the opinion that this is the case because present outcome measures do not capture real-life situations. We propose that the concept of recovery should be carefully defined and that the gold standard of outcome should incorporate social and clinical parameters. We define recovery and discuss remission in full within the body of the paper. In short we propose that within the definition of recovery, personal growth, supportive relationships, and social inclusion should be incorporated. With the new definition the following will be addressed when assessing outcome:1)Symptom manifestation,2)Response to treatment,3)Impact on self & others.We also hope that with a new definition the following three dimensions will be addressable:1)Clinical remission,2)Presence of side effects,3)social outcome.Finally, the reassessment of recovery should be sensitive to culture, be comprehensive, and reliable.
P03-138 - Training Working Memory in Schizophrenia
Authors: Penner I.-K. , Hubacher M. , Vogt A. , Calabrese P. , Weiland M. , Opwis K. , Stoppe G. 
Published: June 2010

BackgroundCognitive deficits in schizophrenia consist of deficits in attention, concentration, fluency, and executive function. Especially the working memory deficits influence everyday function and rehabilitation.ObjectiveThe ame of the study was to investigate a potential of a neurocognitive intervention in schizophrenia (CS) and multiple sclerosis (MS) by application of a computerised working memory training.MethodsSo far, 30 ms patients and 14 cs patients were investigated. Patients are allocated to a treatment group or to a control design. At baseline, all participants underwent a comprehensive neuropsychological examination including memory, working memory, attention, concentration, information processing speed, mental flexibility and intelligence. The treatment group performed a computer program (Brainstim®) four times a week over a period of four weeks. After 16 training sessions all participants were evaluated again neuropsychologically.ResultsIn both patient groups a significant increase in cognitive performance within the training procedure could be shown. This increase was expressed by an initial exponential function with a steep increase and an asymptotic slope. Pre-post-test-comparisons revealed significant improvement for shortterm and working memory on the neuropsychological outcomes. The program was well accepted by the patients.ConclusionThis preliminary results show, that working memory might be trained in schizophrenia and thus it might interfere positively the cognitive und rehabilitative outcome.
P03-139 - The First Experience of Acoustic Startle Response Prepulse Modification Measurement in Russian Patients with Schizophrenia and Healthy Controls
Authors: Storozheva Z. , Bogdanov K. , Novototsky-Vlasov V. , Samylkin D. , Kirenskaya A. 
Published: June 2010

ObjectivesEstimation of acoustic startle response (ASR) and its prepulse modification in Russian population of patients with schizophrenia and healthy controls.MethodsAll subjects were males 25-50 years old. ASR was measured bilaterally by orbicularis oculi electromyographic response to 50 ms 110 dB white band noise. Prepulse at lead intervals of 60, 120 and 2500 ms were delivered according to protocol, recommended by Consortium on the genetics of schizophrenia.ResultsASR magnitude to pulse alone trials in initial block and habituation didn’t differ significantly between patients and controls. Patients compared to controls displayed reduced magnitude prepulse inhibition that was significant at 60 ms lead interval and reduction was more pronounced at the left eye. Startle latency prepulse facilitation at 60 ms lead interval was observed in patients but not in controls whereas prepulse inhibition of startle latency at 120 ms lead interval was seen in controls but not in patients. ASR amplitude prepulse facilitation (PPF) at 2500 ms lead interval was impaired in patients and this deficit was observed only in drug-naïve subjects. Effects of head trauma and experience of psychoactive drugs intake on ASR prepulse modification were revealed only in controls. High initial amplitude and short ASR latency in patients correlated with excitation level (PANSS scale P4). At the same time, PPF reduction correlated with scales P2, P4, P5, P7 and sum of positive PANSS scales.ConclusionsResults of present study testify the possibility of ASR prepulse modification use for schizophrenia endophenotyping in Russia.
P03-140 - Neurotransmitters Blood Level, ASR Prepulse Modification and Antisaccades Deficits in Schizophrenia: Implication for Identification of Schizophrenia Endophenotypes
Authors: Storozheva Z. , Kirenskaya A. , Bogdanov K. , Novototsky-Vlasov V. , Samylkin D. 
Published: June 2010

ObjectivesStudy of psychophysiological candidate schizophrenia endophenotypes in relation with neurotransmitters blood level and mental disorders.Methods23 patients with schizophrenia and 24 healthy subjects performed horizontal antisaccades. Acoustic startle response (ASR) prepulse modification was studied according to protocol, recommended by Consortium on the genetics of schizophrenia. Neurotransmitters blood plasma level was estimated using HPLC.ResultsSignificant increase of errors and saccade latencies was revealed in patients compared to controls. ASR prepulse inhibition (PPI) at 60 ms lead interval and ASR prepulse facilitation (PPF) at 2500 ms lead interval were impaired in patients. Analysis didn’t reveal any correlations between ASR and antisaccades measures in patients while in healthy controls high initial ASR amplitude correlated with incorrect antisaccades number and PPF level correlated with antisaccades latencies. Significantly higher individual variability of plasma serotonin, glutamate and taurine content was found in patients compared to controls. Positive correlations of PPI with glutamate and taurine content were observed in patients but not in controls. At the same time, correlation between PPI and serotonine turnover ratio was positive in control group and negative in patients. Antisaccade latencies in controls displayed negative correlation with DOPAC and taurine level while in patients they positively correlated with dopamine and negatively with serotonine turnover ratio. It was also found that antisaccades parameters and ASR measures displayed correlations with different PANSS scales.ConclusionThese data support the hypothesis that PPI and antisaccades are associated with different neural networks and have different genetic aetiology.
P03-141 - The Sleep and Quality of Life in Schizophrenia
Authors: Tel H. , Doğan S. 
Published: June 2010

ObjectivesSchizophrenia is a chronic and potentially devastating disease. Patients with schizophrenia have severe and persistent sleep disturbance. Sleep deprivation may foster poor functioning and high levels of thought disorder, hostility, and excitement. Sleep deprivation in patients with schizophrenia have a negative impact on HRQoL. This study was done, as definitive study, to determine the sleep quality and quality of life in schizophrenia.Methods72 schizophrenic inpatients treated in a mental health care centre with the diagnosis of schizophrenia between March 1st and May 31st, 2009 were included to the study. The data was gathered through personal data forms, PSQI and WHOQOL-Brief Turkish Version.ResultsIt was found that there was a meaningful relationship between the age, sleep quality and quality of life of the patients (p< 0.05), it was also defined that sleep quality decreased as the age increased and quality of life decreased since the quality of sleep was decreased. The life quality points, except physical field, of the patients who live alone, hospitalized more than three times a year, do not use their medicine regularly were defined low.ConclusionsThere is a close relationship between the sleep quality and quality of life of the schizophrenia. As the sleep quality diminished, their quality of life decreases. The quality of life of the schizophrenia may be increased by regulating their sleep pattern and supporting their adoption to the illness.
P03-145 - Addiction Syndrome in Schizophrenia: One Independent Dimension
Authors: Vargas M.L. , Lopez S. 
Published: June 2010

ObjectivesAddictive disorders are frequent in schizophrenia and dual diagnose is the norm rather than the exception. Dopamine transmission is implicated both in addictive disorders as in psychotic diseases. The objective is to know if addiction is one independent dimension in schizophrenia or if it can be included in to the positive, negative or affective syndromes.MethodsWe conduct one cross-sectional study on 60 schizophrenia out-patients (43 male; average age: 38.9 years, SD 9.4). The diagnosis were: paranoid schizophrenia 26.7%, schizoaffective disorder 25.0%, residual schizophrenia 21.7%, other schizophrenia subtypes 26.6%. It was applied the PANSS and one addiction composite score (ACS) that reflects the life use of drugs and addiction: tobacco, coffee, alcohol, cannabis, cocaine, amphetamines, hallucinogens, opiates and gambling. For every substance and gambling were scored: first use, frequency, length of use, last time use and harmful consequences. All the scores were transformed in to Z values. Factor analysis using principal components (Varimax rotation) was performed introducing in the model: PANSS positive and negative items, depression item an the ACS.ResultsFive factors were defined, that explains for 78.4 of the variance: negative (N1, N2, N3, N4, N6), disorganized (P2, P4, N5, N7), positive and depressive (P1, P3, G6), hostility (P5, P6, P7) and addictive (ACS).ConclusionsAddiction is one independent dimension in schizophrenia, differentiated from positive, negative, disorganized and hostility syndromes. We propose the systematic study of addiction as one intrinsic dimension of schizophrenia due to its independence of other dimensions, its high prevalence and its clinical relevance.
P03-148 - Psychosocial Functioning in Remitted and Non-Remitted Schizophrenic Patients
Authors: Volpe U. , Avolio D. , Capuano M. , Bucci P. , Piegari G. , Campana T. , Mucci A. , Galderisi S. 
Published: June 2010

ObjectivesSymptomatic remission is increasingly perceived as a realistic objective of pharmacological treatment in patients with schizophrenia (2). However the relationships between symptomatic remission, as defined by standardized criteria, and functional outcome remain controversial. In the present study, we designed a one-year follow-up of clinically stable patients with schizophrenia and examined the relationships of clinical remission with several indices of psychosocial functioning.MethodsThirty-six patients with schizophrenia were included. All the evaluations were carried out both at baseline (T0) and after a one-year follow-up (T12). The categorization in psychosocial remission/non-remission was done by means of the Psychosocial Remission in Schizophrenia (PSRS) scale.ResultsBoth at T0 and at T12, R showed, with respect to NR, a better social functioning and a better quality of life. Correlation analysis revealed that the better the psychosocial functioning, the lower the scores on all psychopathological dimensions, except “anxiety/depression” and “hostility” at T0 as well as “anxiety/depression” at T12. At T0, 65% of R resulted also in psychosocial remission; at T12, this percentage reached 90%.ConclusionsOur findings suggest that symptomatic remission in schizophrenia is associated to functional outcome in the majority of cases, especially when both symptomatic and chronological criteria are met.
P03-15 - Evaluation of Sedative Effects of Antipsychotic Drugs Based on EEG, Psychomotor Vigilance Task and Ratings Scales
Authors: Wichniak A. , Wierzbicka A. , Waliniowska E. , Musinska I. , Czasak K. , Jakubczyk T. , Jernajczyk W. , Jarema M. 
Published: June 2010

ObjectivesPersistent sedation is a side effect of antipsychotic drugs, with a substantial impact on quality of live and treatment adherence. Additionally sedation can contribute to weight gain and metabolic disturbances. It impairs also patient's driving skills. In present study we evaluated sedative effects of antipsychotic drugs using three methods that are accessible, and easy to use in psychiatric practice.Methods59 patients with schizophrenia (mean age 25.1 ± 3.6, 27 M, 22 F) were included to the study before the discharge from an open psychiatric ward. All patients underwent monotherapy with sedative (olanzapine; n=33, mean dose 15.4 ± 5.9), moderate -sedative (risperidone; n=12, mean dose 4.4 ± 1.8) and non-sedative (aripiprazole, sertindole; n=14, mean dose 18.7 ± 6.2, 15.5 ± 3.3) antipsychotics. The patients underwent EEG recordings, 28-minutes long psychomotor vigilance task (Mackworth Clock Test) and filled out Epworth Sleepiness Scale (ESS) and scales for assessment of sleep quality.ResultsIncreased slow-wave EEG activity was found in 21 (63.6%) of patients treated with olanzapine, 8 (66.7%) of patients treated with risperidone and 3 (21.4%) of patients treated with non-sedative antipsychotics (p< 0.05). Abnormal results of psychomotor task were found respectively in 10 (30.3%), 5 (41.7%) and 4 (28.6%) of patients (not significant). Mean ESS score was: 6.9 ± 3.3, 8.0 ± 3.0, 5.4 ± 3.7, respectively (not significant).ConclusionsSigns of sedation were frequent in EEG recordings of patients treated with sedative antipsychotics, however at performance level in psychomotor task the differences between the investigated drugs were less pronounced.
P03-150 - The Demobinc Project: Results of the QuIRC Reliability Testing, Factor Analysis and Service User Assessment
Authors: White S. , Turton P. , Wright C. 
Published: June 2010

ObjectiveTo test the psychometric properties of the Quality Indicator for Rehabilitative Care (QuIRC), refine the toolkit and compare results with service user experiences.MethodsFollowing the initial development of the toolkit, it was translated into the languages of the partner countries and piloted. It was then refined to maximize a) its inter-rater reliability, b) its usability and c) its ability to deliver assessments relevant to each country's established systems of change at local, regional and national level. Managers of participating units were re-interviewed using the refined tool. QuIRC scores were compared against service users’ quality of life, autonomy, experiences of care and markers of recovery to assess whether the QuIRc could provide a proxy-assessment of the unit's promotion of service users’ autonomy and Recovery.ResultsThe tool was piloted in 20 units in each country (a total of 200 units). Inter-rater reliability was assessed using intra-class correlations and Cohen's Kappa coefficients. Factors with low reliability or extreme response biases were dropped. Remaining items were subjected to an exploratory factor analysis to test domain allocation and improve internal consistency. QuIRC domain ratings were compared by country and facility type and with service user assessments. The QuIRC was found to have high reliability, to be easy to use and there was high correlation between domain ratings and service users’ ratings.
P03-151 - A Study of the Genetic Association Between the MYO9B Locus and Schizophrenia in a Chinese Population
Authors: Wu N. , Zhang X. , Jin S. , Liu S. , Ju G. , Wang Z. , Liu L. , Ye L. , Wei J. 
Published: June 2010

ObjectivesAn increasing number of studies have described the relationship between celiac disease and schizophrenia. Based on the reported correlations and the overlapping linkage regions on 19p13, the myosin IXB gene (MYO9B) can be considered a highly relevant positional and functional candidate gene for schizophrenia. The present work was undertaken to investigate the association of the MYO9B gene with schizophrenia in a Chinese population.MethodsA total of 329 patients with schizophrenia and 350 healthy control subjects in a Chinese population were recruited. A PCR-based RFLP protocol was applied to genotype 7 single nucleotide polymorphisms (SNPs), including rs7249490, rs7256689, rs2279007, rs8113494, rs2305767, rs1545620 and rs2305764, in the MYO9B gene to investigate their association with schizophrenia.ResultsThe X2 goodness-of-fit test showed that the genotypic distributions of all 7 SNPs were in Hardy-Weinberg equilibrium in both the patient group and the control group. Disease association was shown for rs8113494 (X2=12.77, P=0.0003, OR=1.89, 95% CI 1.33-2.68) and rs1545620 (X2=15.44, P=8.379e-5, OR=1.65, 95% CI 1.29-2.12), while rs2279007 was associated with schizophrenia in the female subjects (X2=4.637, P=0.031, OR=0.69, 95% CI 0.49-0.97) but not in the male subjects (X2=1.082, P=0.299, OR=0.85, 95% CI 0.63-1.15).ConclusionsThe present work shows that the polymorphisms of the MYO9B gene are likely to confer susceptibility to schizophrenia. Because the MYO9B gene has been found to be highly expressed in the tight junction gate, it could be considered as a meeting point for the interaction between environmental and genetic factors in the pathogenesis of schizophrenia.